Current Clinical Trials
PMC clinical trials for medical professionals
The following trials are currently open at Pikeville Medical Center. To get more information on a area of interest, just click on the study category or type. There are courtesy links in many of the protocol descriptions that link to more detailed information from sites like ClinicalTrials.gov and CTSU.
| Study ID: GOG-0241 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian tube Cancer (MEOC)
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema (N/A) | Physician Fact Sheet |
| Study ID: GOG-0238 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema |
| Study ID: GOG-0249 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema | Physician Fact Sheet |
| Study ID: GOG-0263 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema | Physician Fact Sheet |
| Study ID: GOG-0258 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema | Physician Fact Sheet |
| Study ID: GOG-0262 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A Randomized Phase III Trial of Every-3-weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin Plus Concurrent and Consolidation Bevacizumab (NSC# 704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema | Physician Fact Sheet |
| Study ID: GOG-0261 |
|
| Sponsoring Organization: CTSU |
| Lead Group: GOG |
Title: A Randomized Phase III Trial of Paclitaxel Plus Carbolplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinomas (Mixed Mesodermal Tumors) of the Uterus
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema | Physician Fact Sheet |
| Study ID: E1609: CTSU |
|
| Sponsoring Organization: CTSU |
| Lead Group: NSI |
Title: Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Abstract & Trial Sites | Eligibility Criteria | Schema| Physician Fact Sheet (N/A) |
| Study ID: CA204004 |
|
| Sponsoring Organization: Bristol-Myers Squibb |
| Lead Group: |
Title: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema (N/A) | Physician Fact Sheet (N/A) |
| Study ID: CA204009 |
|
| Sponsoring Organization: Bristol-Myers Squibb |
| Lead Group: |
Title: Phase 2 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Abstract & Trial Sites | Eligibility Criteria (N/A) | Schema (N/A) | Physician Fact Sheet (N/A) |
| Study ID: |
|
| Sponsoring Organization: Pikeville Medical Center |
| Lead Group: Pikeville Medical Center |
| Title: Palliative Care Impact Study. This study will evaluate the impact of palliative care interventions on the system burden, quality of life, patient and family satisfaction, and reduced cost of care post palliative care intervention(s).
|
| Study ID: JOSTENT |
|
| Sponsoring Organization: FDA |
| Lead Group: FDA |
| Title: JOSTENT GraftMaster Coronary Stent Graft approved by FDA as a Humanitarian Device Exemption (HDE)
|
| Study ID: NCT01076764 |
|
| Sponsoring Organization: Sanofi-Aventis |
| Lead Group: Sanofi-Aventis |
Title: Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)
Study information on ClinicalTrials.gov
|
| Study ID: NCT01147250 |
|
| Sponsoring Organization: Sanofi-Aventis |
| Lead Group: Sanofi-Aventis |
Title: Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)
Study information on ClinicalTrials.gov |
| Study ID: NCT01389700 |
|
| Sponsoring Organization: Sanofi-Aventis |
| Lead Group: Sanofi-Aventis |
Title: Pharmacokinetics, Pharmacodynamics and Safety Assessment of SAR279356 in Intensive Care Unit Patients on Mechanical Ventilation
More information on ClinicalTrials.gov |
Privacy Policy | Terms of Use | Comments, Concerns | Joint Commission Contact
Pikeville Medical Center | 911 Bypass Road | Pikeville, KY | 41501606-218-3500
Our mission is to provide quality regional health care in a Christian environment.
©2005-2013 Pikeville Medical Center
E-mail our Webmaster to report Website problems.
Mayo, Mayo Clinic and Mayo Clinic Care Network are trademarks of Mayo Clinic.
| 
Multiple Myeloma (2 studies open)